SandboxAQ Highlights Federated AI Focus in Drug Discovery Webinar

According to a recent LinkedIn post from SandboxAQ, the company is drawing attention to binding affinity as a key bottleneck in early drug discovery now that structure prediction is described as largely solved. The post highlights an upcoming March 24 webinar featuring SandboxAQ’s VP of Drug Discovery, Andrea Bortolato, PhD, alongside representatives from Johnson & Johnson Innovative Medicines and Rhino Federated Computing.

The LinkedIn post suggests the discussion will focus on how federated AI can help organizations collaboratively improve binding affinity models without exposing proprietary data. For investors, this emphasis on federated AI in drug discovery may indicate SandboxAQ’s intent to position its technology within data-sensitive pharma and biotech workflows, potentially enhancing its relevance for partnerships and future revenue opportunities in computational drug discovery.